211 related articles for article (PubMed ID: 36560881)
21. Redox proteome analysis of auranofin exposed ovarian cancer cells (A2780).
Chiappetta G; Gamberi T; Faienza F; Limaj X; Rizza S; Messori L; Filomeni G; Modesti A; Vinh J
Redox Biol; 2022 Jun; 52():102294. PubMed ID: 35358852
[TBL] [Abstract][Full Text] [Related]
22. Glutathione and glutaredoxin act as a backup of human thioredoxin reductase 1 to reduce thioredoxin 1 preventing cell death by aurothioglucose.
Du Y; Zhang H; Lu J; Holmgren A
J Biol Chem; 2012 Nov; 287(45):38210-9. PubMed ID: 22977247
[TBL] [Abstract][Full Text] [Related]
23. Disruption of thioredoxin metabolism enhances the toxicity of transforming growth factor β-activated kinase 1 (TAK1) inhibition in KRAS-mutated colon cancer cells.
Hrabe JE; O'Leary BR; Fath MA; Rodman SN; Button AM; Domann FE; Spitz DR; Mezhir JJ
Redox Biol; 2015 Aug; 5():319-327. PubMed ID: 26114584
[TBL] [Abstract][Full Text] [Related]
24. Glutaminase Inhibitors Induce Thiol-Mediated Oxidative Stress and Radiosensitization in Treatment-Resistant Cervical Cancers.
Rashmi R; Jayachandran K; Zhang J; Menon V; Muhammad N; Zahner M; Ruiz F; Zhang S; Cho K; Wang Y; Huang X; Huang Y; McCormick ML; Rogers BE; Spitz DR; Patti GJ; Schwarz JK
Mol Cancer Ther; 2020 Dec; 19(12):2465-2475. PubMed ID: 33087507
[TBL] [Abstract][Full Text] [Related]
25. Thioredoxin Reductase Inhibition Attenuates Neonatal Hyperoxic Lung Injury and Enhances Nuclear Factor E2-Related Factor 2 Activation.
Li Q; Wall SB; Ren C; Velten M; Hill CL; Locy ML; Rogers LK; Tipple TE
Am J Respir Cell Mol Biol; 2016 Sep; 55(3):419-28. PubMed ID: 27089175
[TBL] [Abstract][Full Text] [Related]
26. Direct Observation of Methylmercury and Auranofin Binding to Selenocysteine in Thioredoxin Reductase.
Pickering IJ; Cheng Q; Rengifo EM; Nehzati S; Dolgova NV; Kroll T; Sokaras D; George GN; Arnér ESJ
Inorg Chem; 2020 Mar; 59(5):2711-2718. PubMed ID: 32049511
[TBL] [Abstract][Full Text] [Related]
27. Targeting redox homeostasis in rhabdomyosarcoma cells: GSH-depleting agents enhance auranofin-induced cell death.
Habermann KJ; Grünewald L; van Wijk S; Fulda S
Cell Death Dis; 2017 Oct; 8(10):e3067. PubMed ID: 28981107
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma.
Raninga PV; Di Trapani G; Vuckovic S; Bhatia M; Tonissen KF
Oncotarget; 2015 Jun; 6(17):15410-24. PubMed ID: 25945832
[TBL] [Abstract][Full Text] [Related]
29. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
[TBL] [Abstract][Full Text] [Related]
30. Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7-APEH-Proteasome Axis in High-grade Serous Ovarian Carcinoma.
Tangri A; Lighty K; Loganathan J; Mesmar F; Podicheti R; Zhang C; Iwanicki M; Drapkin R; Nakshatri H; Mitra S
Mol Cancer Res; 2021 Jul; 19(7):1168-1181. PubMed ID: 33753553
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells.
Marzano C; Gandin V; Folda A; Scutari G; Bindoli A; Rigobello MP
Free Radic Biol Med; 2007 Mar; 42(6):872-81. PubMed ID: 17320769
[TBL] [Abstract][Full Text] [Related]
32. Treatment of human cancer cells with selenite or tellurite in combination with auranofin enhances cell death due to redox shift.
Rigobello MP; Gandin V; Folda A; Rundlöf AK; Fernandes AP; Bindoli A; Marzano C; Björnstedt M
Free Radic Biol Med; 2009 Sep; 47(6):710-21. PubMed ID: 19486940
[TBL] [Abstract][Full Text] [Related]
33. Auranofin, an inhibitor of thioredoxin reductase, induces apoptosis in hepatocellular carcinoma Hep3B cells by generation of reactive oxygen species.
Hwang-Bo H; Jeong JW; Han MH; Park C; Hong SH; Kim GY; Moon SK; Cheong J; Kim WJ; Yoo YH; Choi YH
Gen Physiol Biophys; 2017 Apr; 36(2):117-128. PubMed ID: 28218611
[TBL] [Abstract][Full Text] [Related]
34. Glutaredoxin 2 reduces both thioredoxin 2 and thioredoxin 1 and protects cells from apoptosis induced by auranofin and 4-hydroxynonenal.
Zhang H; Du Y; Zhang X; Lu J; Holmgren A
Antioxid Redox Signal; 2014 Aug; 21(5):669-81. PubMed ID: 24295294
[TBL] [Abstract][Full Text] [Related]
35. Targeting the thioredoxin system as a novel strategy against B-cell acute lymphoblastic leukemia.
Fidyt K; Pastorczak A; Goral A; Szczygiel K; Fendler W; Muchowicz A; Bartlomiejczyk MA; Madzio J; Cyran J; Graczyk-Jarzynka A; Jansen E; Patkowska E; Lech-Maranda E; Pal D; Blair H; Burdzinska A; Pedzisz P; Glodkowska-Mrowka E; Demkow U; Gawle-Krawczyk K; Matysiak M; Winiarska M; Juszczynski P; Mlynarski W; Heidenreich O; Golab J; Firczuk M
Mol Oncol; 2019 May; 13(5):1180-1195. PubMed ID: 30861284
[TBL] [Abstract][Full Text] [Related]
36. TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway.
Qi G; Ma H; Li Y; Peng J; Chen J; Kong B
Cell Death Dis; 2021 Dec; 12(12):1135. PubMed ID: 34876569
[TBL] [Abstract][Full Text] [Related]
37. Upregulation of thioredoxin and its reductase attenuates arsenic trioxide‑induced growth suppression in human pulmonary artery smooth muscle cells by reducing oxidative stress.
Park WH
Oncol Rep; 2020 Jan; 43(1):358-367. PubMed ID: 31789420
[TBL] [Abstract][Full Text] [Related]
38. MYC is sufficient to generate mid-life high-grade serous ovarian and uterine serous carcinomas in a p53-R270H mouse model.
Blackman A; Rees AC; Bowers RR; Jones CM; Vaena SG; Clark MA; Carter S; Villamor ED; Evans D; Emanuel AJ; Fullbright G; Long DT; Spruill L; Romeo MJ; Helke KL; Delaney JR
bioRxiv; 2024 Jan; ():. PubMed ID: 38352443
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of Radiation Response in Breast Cancer Stem Cells by Inhibition of Thioredoxin- and Glutathione-Dependent Metabolism.
Rodman SN; Spence JM; Ronnfeldt TJ; Zhu Y; Solst SR; O'Neill RA; Allen BG; Guan X; Spitz DR; Fath MA
Radiat Res; 2016 Oct; 186(4):385-395. PubMed ID: 27643875
[TBL] [Abstract][Full Text] [Related]
40. Targeting DUSP Activity as a Treatment for High-Grade Serous Ovarian Carcinoma.
Sanders BE; Yamamoto TM; McMellen A; Woodruff ER; Berning A; Post MD; Bitler BG
Mol Cancer Ther; 2022 Aug; 21(8):1285-1295. PubMed ID: 35587258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
